Medical Community Comments

MDAnderson logo

Ara A. Vaporciyan, M.D., F.A.C.S.
Director of Clinical Education & Training
Department of Thoracic & Cardiovascular Surgery
The University of Texas
MD Anderson Cancer Center

“There is a significant body of evidence demonstrating that angiogenic factors could enhance the development of microcirculation thus preserving and even reviving infracted or damaged heart muscle. One of the problems with any of this biologic therapy has been targeting the therapy appropriately, whether it be biologic therapy in cancer or biologic therapy in myocardial disease. The ability to place a catheter in the pericardial space and bathe the cardiac mycardium in angiogenic factors would be an unsurpassed method to deliver potent new agents directly to the target tissue….It could lead to a significant change in the approach to ischemic cardiac disease, which is, of course, the number one killer of adults in America.”

Click here for entire letter.



Michael P. Macris, M.D.
Medical Director, Cardiovascular Services NW
Memorial Hermann Hospital System
Chief Medical Officer, Cormedics Corporation

“Having used the PeriPort device in its various iterations…including human cadavers and open-heart surgery patients, I am very confident that the device will be both safe and effective for the removal of fluid in the pericardial space.”

“With regard to the deployment of drugs and/or devices for IPC [intrapericardial] therapy, I can offer an overview of the world literature which very strongly suggests that this new route of administration holds great promise for a very large number of applications. In general, as far as virtually all IPC drug studies have shown, drugs administered directly to the pericardial space have much higher drug effects, with much lower (and again, cheaper) dosages, while at the same time showing dramatically lower side-effects.”

“Lastly, as far as the deployment of devices, I believe that the general trend in cardiac surgery…has been overwhelmingly in the direction of the avoidance of sternotomy and thoracotomy, such that accessing the heart via the subxyphoid [Cormedics] approach just makes good sense to anyone pursuing minimally-invasive device deployment.” “..the device has a very solid foundation…and it should reach clinical fruition in a wide variety of applications.”

Click here for entire letter.



William E. Cohn, MD
Director, Minimally Invasive Surgical Technology
Associate Director, Laboratory Surgery Research – Center for Cardiac Support
Texas Heart Institute @ St. Luke’s Episcopal Hospital
Associate Professor of Surgery, Baylor College of Medicine

“As you know I have been experimenting with early generations of your pericardial ‘dry tap’ (accessing the pericardial space percutaneously in patients without pericardial effusion) device and I think it has real merit. …I am certain that intrapericardial therapeutics represents a huge emerging opportunity…(in which) an enabling technology (like yours…) that facilitates dry tap would be readily embraced by the Electrophysiology community as new epicardial technologies continue to be introduced.”

“I imagine that, as this space continues to evolve…exciting opportunities for you and your device will develop. I think you’ve timed your efforts perfectly”

Click here for entire letter.

Additional testimonials available upon request.